These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19002391)

  • 41. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.
    Ann Intern Med; 1995 Nov; 123(9):656-64. PubMed ID: 7574220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Fate of polycythemia vera treated by radioactive phosphorus. Apropos of a series of 303 patients followed for 12 to 24 years].
    Tubiana M; Attie E; Parmentier C
    Nouv Presse Med; 1975 Jun; 4(24):1781-6. PubMed ID: 1161478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
    Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
    Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
    Cerquozzi S; Tefferi A
    Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
    Passamonti F; Brusamolino E; Lazzarino M; Baraté C; Klersy C; Orlandi E; Canevari A; Castelli G; Merante S; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1011-8. PubMed ID: 11025590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.
    Barosi G; Ambrosetti A; Buratti A; Finelli C; Liberato NL; Quaglini S; Ricetti MM; Visani G; Tura S; Ascari E
    Leukemia; 1993 Feb; 7(2):200-6. PubMed ID: 8426474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
    Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
    Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A; Gray LA; Reeder T; Schroeder G; Kaufmann SH
    Leukemia; 2003 May; 17(5):849-55. PubMed ID: 12750696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Post-polycythemia myeloid metaplasia: experience with a large cohort of patients.
    Randi ML; Barbone E; Fabris F; Varotto L; Macri C; Girolami A
    J Med; 1994; 25(6):363-9. PubMed ID: 7769374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
    Chou YS; Gau JP; Yu YB; Pai JT; Hsiao LT; Liu JH; Hong YC; Liu CY; Yang CF; Chen PM; Chiou TJ; Tzeng CH
    Eur J Haematol; 2013 Mar; 90(3):228-36. PubMed ID: 23281576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progression of polycythaemia vera to malignant myelofibrosis and reticulum cell sarcoma.
    McVie JG; McMichael AC; Ramsay DM
    Scand J Haematol; 1974; 13(1):61-3. PubMed ID: 4606950
    [No Abstract]   [Full Text] [Related]  

  • 56. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival.
    Abu-Zeinah G; Krichevsky S; Cruz T; Hoberman G; Jaber D; Savage N; Sosner C; Ritchie EK; Scandura JM; Silver RT
    Leukemia; 2021 Sep; 35(9):2592-2601. PubMed ID: 33654206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
    Szuber N; Mudireddy M; Nicolosi M; Penna D; Vallapureddy RR; Lasho TL; Finke C; Begna KH; Elliott MA; Hook CC; Wolanskyj AP; Patnaik MM; Hanson CA; Ketterling RP; Sirhan S; Pardanani A; Gangat N; Busque L; Tefferi A
    Mayo Clin Proc; 2019 Apr; 94(4):599-610. PubMed ID: 30824279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.
    Vaidya R; Gangat N; Jimma T; Finke CM; Lasho TL; Pardanani A; Tefferi A
    Am J Hematol; 2012 Nov; 87(11):1003-5. PubMed ID: 22965887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.